Back
Apellis Pharmaceuticals Quote, Financials, Valuation and Earnings
Sponsored
APLS
Sponsored
NOW is the time to get in on this trillion-dollar megatrend
Get it here.
Sell
25
APLS
Apellis Pharmaceuticals
Last Price:
44.18
Seasonality Move:
-1.82%
7 Day Trial
ALL ACCESS PASS
$
7
Earn Your Weekly "Paycheck" with Chuck's Secret Income Strategy!
Act now for your path to extra income!Apellis Pharmaceuticals Price Quote
$44.18
-0.01 (-7.65%)
(Updated: May 1, 2024 at 5:51 AM ET)
Apellis Pharmaceuticals Key Stats
Sell
25
Apellis Pharmaceuticals (APLS)
is a Sell
Day range:
$38.22 - $46.85
52-week range:
$19.83 - $94.75
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.22
P/B ratio:
27.39%
Volume:
6.4M
Avg. volume:
1.4M
1-year change:
-47.03%
Market cap:
$5.3B
Revenue:
$396.6M
EPS:
$-4.48
How Much Does Apellis Pharmaceuticals Make?
-
How Much Are Apellis Pharmaceuticals's Sales Annually?
APLS Revenues are $396.6M -
How Much Profit Does Apellis Pharmaceuticals's Make A Year?
APLS net income is -$528.6M
Is Apellis Pharmaceuticals Growing As A Company?
-
What Is Apellis Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 5.46% -
What Is Apellis Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Apellis Pharmaceuticals Stock Price Performance
-
Did Apellis Pharmaceuticals Stock Go Up Last Month?
Apellis Pharmaceuticals share price went down by -24.82% last month -
Did APLS's Share Price Rise Over The Last Year?
APLS share price fell by -47.03% over the past 1 year
What Is Apellis Pharmaceuticals 52-Week High & Low?
-
What Is Apellis Pharmaceuticals’s 52-Week High Share Price?
Apellis Pharmaceuticals has traded as high as $94.75 over the past 52 weeks -
What Is Apellis Pharmaceuticals’s 52-Week Low Share Price?
Apellis Pharmaceuticals has traded as low as $19.83 over the past 52 weeks
Apellis Pharmaceuticals Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Apellis Pharmaceuticals?
-
How Much Debt Does Apellis Pharmaceuticals Have?
Total long term debt quarterly is $93M -
How Much Cash Does Apellis Pharmaceuticals Have?
Cash and short term investments quarterly total is $351.2M -
What Is Apellis Pharmaceuticals’s Book Value Per Share?
Book value per share is 1.63
Is Apellis Pharmaceuticals Cash Flow Positive?
-
What Is APLS Cash Flow From Operations?
Cash flow from operations (TTM) is -$594.7M -
What Is Apellis Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $394.5M -
What Is Apellis Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$674K
Apellis Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
APLS return on invested capital is -145.34% -
What Is Apellis Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is -62.02% -
What Is APLS Return On Equity?
ROE is a measure of profitability and is -195.18%
Apellis Pharmaceuticals Earnings Date & Stock Price
-
What Is Apellis Pharmaceuticals's Stock Price Today?
A single share of APLS can be purchased today for 44.19 -
What Is Apellis Pharmaceuticals’s Stock Symbol?
Apellis Pharmaceuticals trades on the nasdaq under the ticker symbol: APLS -
When Is Apellis Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Apellis Pharmaceuticals is scheduled on May 7, 2024 -
When Is APLS's next ex-dividend date?
Apellis Pharmaceuticals's next ex-dividend date is May 1, 2024 -
How To Buy Apellis Pharmaceuticals Stock?
You can buy Apellis Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Apellis Pharmaceuticals Competitors
-
Who Are Apellis Pharmaceuticals's Competitors?
Below is a list of companies who compete with Apellis Pharmaceuticals or are related in some way:
Apellis Pharmaceuticals Dividend Yield
Data Unavailable
Apellis Pharmaceuticals Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | -3.73% |
Revenue: | 545.89% | 1.94% |
Analyst Recommendations
Buy Recommendations: | 11 |
---|---|
Hold Recommendations: | 3 |
Sell Recommendations: | 0 |
Price Target: | 81.54 |
Upside from Last Price: | 84.52% |